TABLE 4.
Multivariable Cox regression models on overall survival and physician‐assessed progression‐free survival from 1L treatment initiation
| Covariate | Level | Total | Event (censored) | HR (95%CI) | P‐value |
|---|---|---|---|---|---|
| OS | |||||
| Age at 1L initiation | Per year increase | 224 | 106 (118) | 1.044 (1.027, 1.063) | <.0001 |
| Stage at diagnosis | Stage I/II (reference) | 21 | 9 (12) | ‐‐ | ‐‐ |
| Stage III/IV | 167 | 91 (76) | 2.053 (1.025, 4.111) | .0423 | |
| No information | 36 | 6 (30) | 0.867 (0.301, 2.497) | .7914 | |
| Presence of brain metastases | No (reference) | 154 | 64 (90) | ‐‐ | ‐‐ |
| Yes | 70 | 42 (28) | 2.192 (1.452, 3.309) | .0002 | |
| 1L treatment | BRAF/MEKi (reference) | 143 | 80 (63) | ‐‐ | ‐‐ |
| aPD‐1 | 81 | 26 (55) | 0.602 (0.382, 0.949) | .0287 | |
| LDH result | Normal (reference) | 93 | 41 (52) | ‐‐ | ‐‐ |
| Elevated | 53 | 32 (21) | 2.146 (1.327, 3.471) | .0019 | |
| Not documented | 78 | 33 (45) | 1.094 (0.683, 1.752) | .7082 | |
| rwPFS | |||||
| Surgical resection prior to 1L initiation | No (reference) | 69 | 51 (18) | ‐‐ | ‐‐ |
| Yes | 155 | 117 (38) | 0.749 (0.536, 1.047) | .0905 | |
| Radiation prior to 1L initiation | No (reference) | 139 | 95 (44) | ‐‐ | ‐‐ |
| Yes | 85 | 73 (12) | 1.793 (1.303, 2.466) | .0003 | |
| 1L treatment group ‐ patients with rwPFS time < 6 months | BRAF/MEKi (reference) | 66 | 61 (5) | ‐‐ | ‐‐ |
| aPD‐1 | 44 | 35 (9) | 1.146 (0.755, 1.738) | .522 | |
| 1L treatment group ‐ patients with rwPFS time ≥ 6 months | BRAF/MEKi (reference) | 77 | 61 (16) | ‐‐ | ‐‐ |
| aPD‐1 | 37 | 11 (26) | 0.228 (0.106, 0.493) | .0002 | |
Abbreviations: 1L, first‐line; aPD‐1, anti‐PD‐1 monotherapies; BRAF/MEKi, BRAF/MEK inhibitors; CI, confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase; OS, overall survival; rwPFS, physician‐assessed progression‐free survival.